Puhr, H. C.
Wolf, P.
Berghoff, A. S.
Schoppmann, S. F.
Preusser, M.
Ilhan-Mutlu, Aysegul http://orcid.org/0000-0001-8291-0873
Funding for this research was provided by:
Medizinische Universität Wien (n.a.)
Article History
Received: 13 October 2019
Accepted: 15 December 2019
First Online: 28 December 2019
Compliance with Ethical Standards
:
: HC.P. has received travel support from Eli Lilly, MSD, Novartis, Pfizer, and Roche.AS.B. has research support from Daiichi Sankyo and Roche; honoraria for lectures, consultation, or advisory board participation from Roche, Bristol-Myers Squibb, Merck, and Daiichi Sankyo; as well as travel support from Roche, Amgen, Daiichi Sankyo, and AbbVie. M.P. has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp and Dohme.A.I-M. participated in advisory boards from MSD and Servier, received lecture honoraria from Eli Lilly and Servier, and is the local PI for clinical trials sponsored by BMS and Astellas.Other authors have nothing to declare.
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. Due to the retrospective design, no separate informed consent was necessary in the scope of this study. The study was approved by the ethics committee of the Medical University of Vienna (signee Jürgen Zezula, reference number: 2267/2016).